Doherty Catherine T. sold 5,990 shares of QUEST DIAGNOSTICS INC at $246.26 for −$1.48M on Nov 3, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Executive Vice President
Executive Vice President
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,475,126.75Shares × reported price
Shares traded
5,990Common Stock
Price per share
$246.26Reported price. Read footnotes for ranges.
% of reported position traded
6.64%This security and ownership context
Holdings after
84,246Direct
Trade date
Nov 3, 2026Sell
Filed
Nov 5, 2026, 7:05 PM ET3-day reporting delay
Accession
0001022079-26-000122Code S · Transaction 394044
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 90,236 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 3, 2026Option exercise22,105$121.81$2,692,499.53Trade 394042
Nov 3, 2026Grant4,827$0.00$0Trade 394041
Nov 3, 2026Option exercise22,105$121.81−$2,692,499.53Trade 394050
Nov 3, 2026Sell3,818$245.45−$937,135.35Trade 394043
Nov 3, 2026Sell1,151$246.98−$284,278.01Trade 394045
Nov 3, 2026Sell2,358$248.38−$585,689Trade 394046
Nov 3, 2026Sell3,004$249.40−$749,208.11Trade 394047
Nov 3, 2026Sell2,877$250.49−$720,654.55Trade 394048
Nov 3, 2026Sell2,907$251.24−$730,350.61Trade 394049
10 transaction rows in this filing. Joint filers share the same rows.

DGX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DGX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −8.7%1w ago −5.1%1d ago −1.9%
Returns since7d +1.6%30d90d180d1y

Footnotes in full

F1: Represents an award of restricted stock units. F2: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5: This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6: This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7: This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9: This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11: The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024.